IL22 and Alzheimer disease: As depicted in Fig. 4, in all three tested conditions (ns, AD like conditions, psoriasis like conditions) GATA3 silencing resulted in significantly reduced GATA3 expression when compared to the control cells (GATA3 shRNA vs control: ns p = 0,0156; IL-4, IL-13 p = 0,0391; IL-22, OSM, IL-17, TNFα p = 0,0391 (all Wilcoxon signed rank test)).